In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
Article Details
- CitationCopy to clipboard
Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA
In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.
Br J Clin Pharmacol. 2000 Apr;49(4):343-51. doi: 10.1046/j.1365-2125.2000.00175.x.
- PubMed ID
- 10759690 [ View in PubMed]
- Abstract
AIMS: To examine the potency of ticlopidine (TCL) as an inhibitor of cytochrome P450s (CYP450s) in vitro using human liver microsomes (HLMs) and recombinant human CYP450s. METHODS: Isoform-specific substrate probes of CYP1A2, 2C19, 2C9, 2D6, 2E1 and 3A4 were incubated in HLMs or recombinant CYPs with or without TCL. Preliminary data were generated to simulate an appropriate range of substrate and inhibitor concentrations to construct Dixon plots. In order to estimate accurately inhibition constants (Ki values) of TCL and determine the type of inhibition, data from experiments with three different HLMs for each isoform were fitted to relevant nonlinear regression enzyme inhibition models by WinNonlin. RESULTS: TCL was a potent, competitive inhibitor of CYP2C19 (Ki = 1.2 +/- 0.5 microM) and of CYP2D6 (Ki = 3.4 +/- 0.3 microM). These Ki values fell within the therapeutic steady-state plasma concentrations of TCL (1-3 microM). TCL was also a moderate inhibitor of CYP1A2 (Ki = 49 +/- 19 microM) and a weak inhibitor of CYP2C9 (Ki > 75 microM), but its effect on the activities of CYP2E1 (Ki = 584 +/- 48 microM) and CYP3A (> 1000 microM) was marginal. CONCLUSIONS: TCL appears to be a broad-spectrum inhibitor of the CYP isoforms, but clinically significant adverse drug interactions are most likely with drugs that are substrates of CYP2C19 or CYP2D6.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Ticlopidine Cytochrome P450 1A2 Protein Humans UnknownInhibitorDetails Ticlopidine Cytochrome P450 2D6 Protein Humans UnknownSubstrateInhibitorDetails Ticlopidine Cytochrome P450 2E1 Protein Humans UnknownInhibitorDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareAbrocitinibSertraline The metabolism of Abrocitinib can be decreased when combined with Sertraline. AbrocitinibDexlansoprazole The metabolism of Abrocitinib can be decreased when combined with Dexlansoprazole. AbrocitinibDiazepam The metabolism of Abrocitinib can be decreased when combined with Diazepam. AbrocitinibPentobarbital The metabolism of Abrocitinib can be decreased when combined with Pentobarbital. AbrocitinibMethadone The metabolism of Abrocitinib can be decreased when combined with Methadone.